Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04818177 · ClinicalTrials.gov registry record

Immunoglobulin G Therapy Dose Optimization

A clinical trial of Obesity and Immune Deficiency, sponsored by Rutgers, The State University of New Jersey.

Completed
Registry status
40
Enrollment target
1
Study location

NCT04818177: Completed study of Obesity and Immune Deficiency, sponsored by Rutgers, The State University of New Jersey.

NCT04818177 is a study of Obesity and Immune Deficiency that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04818177, a study of Obesity and Immune Deficiency, has completed, sponsored by Rutgers, The State University of New Jersey.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. Obesity poses significant health risks; and evidence supporting dosing strategies of IgG in obese patients is inadequate. Some of the adverse reactions have been attributed to a relative overdosing in these patients, due to a limited distribution of IgG into fat tissue.

Primary Outcome

A linear mixed effects model to analyze serum IgG concentrations, with normal/obese as the primary predictor but with clinical and demographic variables as covariates.

Interventions

  • DRUG Institutional standard intravenous immune globulin treatment

Study Locations (1)

New Jersey

  • Robert Wood Johnson University Hospital Somerset - Somerville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-04-01
Est. Completion 2025-08-01

What the finished NCT04818177 record still lists

NCT04818177 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Institutional standard intravenous immune globulin treatment is the first listed.

NCT04818177 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT04818177 about?

NCT04818177 is a clinical study titled "Immunoglobulin G Therapy Dose Optimization". The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. ...

What is the current status of trial NCT04818177?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2021-04-01. Estimated completion is 2025-08-01.

What conditions does trial NCT04818177 study?

This clinical trial studies the following conditions: Obesity, Immune Deficiency.

What interventions are being tested in trial NCT04818177?

The interventions under investigation include: Institutional standard intravenous immune globulin treatment (DRUG).

Who is sponsoring clinical trial NCT04818177?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04818177 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04818177's enrollment target sits among peer trials

40 778th of 1053 higher than 249 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04818177, the US trial registry maintained by the National Library of Medicine. NCT04818177 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.